BCRX

Rating neutralAI Memo

BioCryst

As of 2026-04-28/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

BCX17725 Phase 1 data by year-end 2026 • 2026-12-31

Expected move: +15%

Biggest risk

The bear case is that the equity still depends heavily on concentrated ORLADEYO execution while navenibart remains pre-approval and BCX17725 remains early stage. Management also disclosed first-quarter payer reauthorization seasonality, competitive HAE programs in Phase 3, and merger-related leverage and integration risks after the Astria transaction. [#IR-2026-01-23] [#10-K-2026-02-26]

Invalidation

Break below $7 or thesis failure.

What would change my mind?

The bull case is that BioCryst has moved from a single-product commercialization story toward a broader HAE platform: 2025 ORLADEYO revenue reached $601.8 million, 2026 ORLADEYO guidance was maintained at $625 million to $645 million, profitability improved, pediatric expansion added reach, and navenibart gives the company a potentially differentiated long-acting prophylaxis asset. [#8-K-2026-02-26] [#10-K-2026-02-26]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-28

Base target

$11

p=50%

Bull target

$14

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

May 6, 2026 Q1 update is the next execution check on ORLADEYO
Navenibart Phase 3 execution toward end-2027 filing
The bull case is that BioCryst has moved from a single-product commercialization story toward a broader HAE platform: 2025 ORLADEYO revenue reached $601.8 million, 2026 ORLADEYO guidance was maintained at $625 million to $645 million, profitability improved, pediatric expansion added reach, and navenibart gives the company a potentially differentiated long-acting prophylaxis asset.

BearKey bullets

BCX17725 is still an early Phase 1 program, so proof-of-concept and commercial relevance remain uncertain.
[#8-K-2026-02-26]
BioCryst incurred significant additional indebtedness to fund the Astria acquisition, with Blackstone financing and share issuance adding leverage and dilution risk.

WatchKey bullets

BCX17725 Phase 1 data by year-end 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $11 (p=50%)

Bull/Bear spread: +48% / -29%

Vs latest close: Bull +48% · Base +15% · Bear -29%

Scenario probabilities

Bull Target: $14 (p=25%)Base Target: $11 (p=50%)Bear Target: $7 (p=25%)

Commentary

Primary-source evidence still supports a constructive but cautious monitoring view rather than a strong bullish thesis. BioCryst entered 2026 with maintained ORLADEYO guidance, first-time profitability, pediatric label expansion, and an expanded HAE platform after acquiring Astria, but the next stock-moving proof point is still the May 6, 2026 quarterly update and whether seasonal payer dynamics disrupt the full-year setup. Recent headline flow is light, trusted-news coverage in the packet is sparse, and no robust analyst-revision set was confirmed, so confidence should stay moderate rather than aggressive. [#IR-2026-04-15] [#IR-2026-01-23] [#8-K-2026-02-26] [#10-K-2026-02-26]

As of 2026-04-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

May 6, 2026 Q1 update is the next execution check on ORLADEYO
Navenibart Phase 3 execution toward end-2027 filing

Scenarios

Bull Target (Scenario probability)

$14 / p=25% prob

Base Target (Scenario probability)

$11 / p=50% prob

Bear Target (Scenario probability)

$7 / p=25% prob

Price $9 as of 2026-05-27

Nearest Scenario: Base (∆ 15%)

Targets vs latest close: Bull +48% · Base +15% · Bear -29%

Sentiment & Exposure

News Sentiment (30d)

57.00

Social Sentiment (7d)

50.00

Events

Other notable items detected

EVENT2026-12-31
BCX17725 Phase 1 data by year-end 2026
BioCryst said BCX17725, a KLK5 inhibitor for Netherton syndrome, is enrolling and dosing, with data expected in up to 12 patients by the end of 2026. This is an early-stage but real pipeline catalyst for a company still viewed largely through its HAE franchise. [#8-K-2026-02-26] [#10-K-2026-02-26]
Prob 55.00% • Move 18.00% • Priced-in 24.00%

Short-term Catalysts

Next few weeks

May 6, 2026 Q1 update is the next execution check on ORLADEYO
2026-05-06
BioCryst said on April 15, 2026 that it will report first quarter 2026 results on May 6, 2026. That print matters because management maintained 2026 ORLADEYO revenue guidance at $625 million to $645 million after reporting $601.8 million of 2025 ORLADEYO revenue, while also cautioning that first-quarter payor reauthorizations can temporarily move patients from paid drug to free product. [#IR-2026-04-15] [#8-K-2026-02-26] [#10-K-2026-02-26]
Prob 80% • Move 15% • Priced-in 58%

Long-term Catalysts

Months to a year

Navenibart Phase 3 execution toward end-2027 filing
2027-12-31
BioCryst said navenibart is in Phase 3, ALPHA-ORBIT is enrolling, and the program is on track to support a regulatory filing by the end of 2027 following the Astria acquisition completed in January 2026. The asset expands BioCryst beyond ORLADEYO, but the value unlock is long-dated and still subject to trial execution and competitive HAE readouts. [#IR-2026-01-23] [#8-K-2026-02-26] [#10-K-2026-02-26]
Prob 62% • Move 30% • Priced-in 31%

Risks

BCX17725 is still an early Phase 1 program, so proof-of-concept and commercial relevance remain uncertain. [#8-K-2026-02-26]
BioCryst incurred significant additional indebtedness to fund the Astria acquisition, with Blackstone financing and share issuance adding leverage and dilution risk. [#IR-2026-01-23]
First-quarter payer reauthorization seasonality can temporarily shift ORLADEYO patients from paid drug to free product, making near-term revenue cadence noisy. [#10-K-2026-02-26]
HAE competition is active, with BioCryst's 10-K listing Phase 3 or other advancing competitive programs including Pharvaris and Intellia. [#10-K-2026-02-26]
Navenibart value realization depends on successful Phase 3 enrollment, execution, and regulatory timing through a long-dated end-2027 filing path. [#8-K-2026-02-26]

Peers

Symbol	Summary
PHVS	Pharvaris is a direct HAE competitor because BioCryst's 2025 10-K lists deucrictibant as a Phase 3 oral acute and prophylactic program that could compete with ORLADEYO or navenibart. [#10-K-2026-02-26]
NTLA	Intellia is a meaningful HAE peer because BioCryst's 2025 10-K lists NTLA-2002 as a Phase 3 one-time prophylaxis gene-editing approach, relevant for long-run franchise pressure if durable efficacy is validated. [#10-K-2026-02-26]
DNTH	Dianthus is a looser small-cap rare-disease comparator from the packet rather than a clean HAE operating comp, but it is still useful for framing valuation sensitivity around milestone-driven biotech programs.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-28

AI Stock Memo: BCRX - BioCryst - RankAlpha